EA201291095A1 - Способ получения пероральной лекарственной формы, содержащей финголимод - Google Patents

Способ получения пероральной лекарственной формы, содержащей финголимод

Info

Publication number
EA201291095A1
EA201291095A1 EA201291095A EA201291095A EA201291095A1 EA 201291095 A1 EA201291095 A1 EA 201291095A1 EA 201291095 A EA201291095 A EA 201291095A EA 201291095 A EA201291095 A EA 201291095A EA 201291095 A1 EA201291095 A1 EA 201291095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
form containing
containing fingolimod
oral medical
medical form
fingolimod
Prior art date
Application number
EA201291095A
Other languages
English (en)
Inventor
Яна Пец
Катрин Римкус
Original Assignee
Рациофарм Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рациофарм Гмбх filed Critical Рациофарм Гмбх
Publication of EA201291095A1 publication Critical patent/EA201291095A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Abstract

Изобретение относится к способу получения промежуточного продукта, содержащего финголимод, способу получения гранул, содержащих финголимод, способу получения пероральной лекарственной формы, содержащей финголимод, и соответственно к промежуточным продуктам, гранулам и пероральным лекарственным формам, получаемым указанным способом.
EA201291095A 2010-04-22 2011-04-21 Способ получения пероральной лекарственной формы, содержащей финголимод EA201291095A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010017944 2010-04-22
PCT/EP2011/002051 WO2011131368A2 (en) 2010-04-22 2011-04-21 A method of preparing an oral dosage form comprising fingolimod

Publications (1)

Publication Number Publication Date
EA201291095A1 true EA201291095A1 (ru) 2013-04-30

Family

ID=44626003

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291095A EA201291095A1 (ru) 2010-04-22 2011-04-21 Способ получения пероральной лекарственной формы, содержащей финголимод

Country Status (5)

Country Link
US (1) US20130095177A1 (ru)
EP (1) EP2560619A2 (ru)
CA (1) CA2797029A1 (ru)
EA (1) EA201291095A1 (ru)
WO (1) WO2011131368A2 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
US20140199382A1 (en) * 2013-01-11 2014-07-17 Cadila Healthcare Limited Stable pharmaceutical compositions of an s1p receptor agonist
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
JP6316422B2 (ja) 2013-07-29 2018-04-25 アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ フィンゴリモドの医薬組成物
WO2015104666A2 (en) * 2014-01-09 2015-07-16 Torrent Pharmaceuticals Limited Pharmaceutical composition of fingolimod
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
CN105384649A (zh) * 2014-08-22 2016-03-09 广东东阳光药业有限公司 一种特定粒径的盐酸芬戈莫德及其固体组合物
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
EP3355863A4 (en) * 2015-10-02 2019-06-19 Mylan, Inc STABLE FORMULATIONS OF FINGOLIMOD
CN106619558A (zh) * 2017-02-27 2017-05-10 佛山市弘泰药物研发有限公司 一种芬戈莫德胃溶型微丸片及其制备方法
WO2021259560A1 (en) 2020-06-25 2021-12-30 Omya International Ag Co-ground active(s) comprising product comprising surface-reacted calcium carbonate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008943A1 (en) 1992-10-21 1994-04-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
PE20131352A1 (es) * 2003-04-08 2013-11-14 Novartis Ag Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar
WO2008037421A2 (en) * 2006-09-26 2008-04-03 Novartis Ag Pharmaceutical compositions comprising an s1p modulator

Also Published As

Publication number Publication date
US20130095177A1 (en) 2013-04-18
EP2560619A2 (en) 2013-02-27
CA2797029A1 (en) 2011-10-27
WO2011131368A3 (en) 2011-12-22
WO2011131368A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
EA201291095A1 (ru) Способ получения пероральной лекарственной формы, содержащей финголимод
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
EA201300388A1 (ru) Соединения замещенного бензамида
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MA34091B1 (fr) Anticorps anti-cd40
MY170713A (en) Treatment protocol of diabetes type 2
ZA201302519B (en) Process for making multiparticulate gastroretentive dosage forms
PH12017501035A1 (en) Method for the production of a pharmaceutical delivery system
WO2012016683A3 (en) Oral dosage form of pregabalin
IN2015DN00924A (ru)
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
MX2013006867A (es) Procedimiento para la preparacion de sales de cis-1-amonio-4-alcoxiciclohexanocarbonitrilo.
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
UA116994C2 (uk) Стабілізована аморфна форма агомелатину, спосіб її одержання і фармацевтичні композиції, які її містять
AP2012006308A0 (en) New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them.
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
EA201201007A1 (ru) Твердая фармацевтическая композиция для буккального введения агомелатина
WO2013022410A3 (en) Production method for effervescent formulations comprising dexketoprofen